Jubilant Life Sciences
Jubilant Life Sciences, a prominent player in the pharmaceutical and life sciences sector, is headquartered in Noida, India. Founded in 1978, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in contract manufacturing, active pharmaceutical ingredients (APIs), and drug delivery solutions, Jubilant Life Sciences is recognised for its commitment to quality and innovation. The company’s core offerings, which include a diverse range of generic pharmaceuticals and specialty chemicals, set it apart in a competitive market. With a focus on sustainability and advanced technology, Jubilant Life Sciences has achieved significant milestones, including multiple regulatory approvals and partnerships with leading global firms. This positions the company as a trusted partner in the healthcare industry, dedicated to improving patient outcomes worldwide.
DitchCarbon Score
How does Jubilant Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jubilant Life Sciences's score of 20 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jubilant Life Sciences's reported carbon emissions
In 2023, Jubilant Life Sciences reported total carbon emissions of approximately 66,229,600 kg CO2e. This figure includes 8,492,000 kg CO2e from Scope 1 emissions, 54,703,000 kg CO2e from Scope 2 emissions, and 662,296,000 kg CO2e from Scope 3 emissions. Over the years, the company has shown a trend of reducing its emissions. For instance, in 2019, total emissions were about 98,830,000 kg CO2e, which indicates a significant decrease by 2023. However, specific reduction targets or commitments have not been disclosed, and there are no documented initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. Jubilant Life Sciences continues to focus on its emissions across all scopes, with a notable emphasis on Scope 3 emissions, which represent a substantial portion of their total carbon footprint. The company’s commitment to addressing climate change is evident, although further details on specific reduction strategies or targets would enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jubilant Life Sciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
